蛋白酶体抑制剂对白血病作用的研究进展

Effects of Proteasome Inhibitors on Leukemias——Review

蛋白酶体负责细胞内蛋白的降解,其活性的异常改变是肿瘤发生的标志。研究证实,蛋白酶体抑制剂对许多恶性肿瘤有抗癌活性,第一个获准临床试验和上市的蛋白酶体抑制剂硼替佐米治疗多发性骨髓瘤患者获得了较高的总体有效率和完全缓解率。国外学者也开展了一系列蛋白酶体抑制剂对白血病细胞治疗作用的研究,本文就蛋白酶体抑制剂对浆细胞白血病、慢性淋巴细胞白血病、成人T细胞淋巴瘤/白血病、慢性髓系白血病、急性髓系白血病作用的研究进展作一综述。

The proteasome is primarily responsible for intracellular protein degradation. The abnormality of its activity is sign of tumorigenesis. It was confirmed that proteasome inhibitors have activities against a variety of malignancies. Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale. Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.